LiSyM Scientific Leadership Team (LiSyM programme directorate) ; LiSyM-Krebs Partnering (LiSyM programme directorate) ; Chronic Liver Disease Progression (LiSyM-DP - Pillar II) (LiSyM programme directorate) ; Early Metabolic Injury (LiSyM-EMI - Pillar I) (LiSyM programme directorate) ; Liver Function Diagnostics (LiSyM-LiFuDi - Pillar IV) (LiSyM programme directorate) ; Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP) (LiSyM programme directorate) ; The Hedgehog Signalling Pathway (LiSyM-JGMMS) (LiSyM programme directorate) ; Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF - Pillar III) (LiSyM programme directorate) ; Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF) (LiSyM programme directorate) ; Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM) (LiSyM programme directorate)
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Organisms: Not specified
The incidence of this life-threatening acute-on-chronic liver failure (ACLF) is increasing, and early detection and cure are urgent clinical needs. Pillar III applies a Systems Medicine approach to identify the critical mechanisms of acute-on-chronic liver failure (ACLF) and to foster liver regeneration and repair.
Public web page: Not specified
Organisms: Not specified
Chronic liver diseases (CLD) progression leads to cirrhosis, often cancer, and ultimately to organ failure and death. Because of the complexity of this scenario, a Systems Medicine approach is chosen to develop strategies to better characterize progression and resolution of fibrosis. Pillar II aims to define key molecular mechanisms and structural changes in tissue architecture during the progression of CLD by visualizing and quantifying at a cellular level, tissue and organ scale.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. LiSyM-EMI looks into the transition from steatosis to non-alcoholic steatohepatitis (NASH) as the disease-defining moment in NAFLD. A systems analysis of these early disease events will be performed to elucidate the molecular mechanisms that trigger disease establishment.
Authors: Nachiket Vartak, Georgia Guenther, Florian Joly, Amruta Damle-Vartak, Gudrun Wibbelt, Jörns Fickel, Simone Jörs, Brigitte Begher-Tibbe, Adrian Friebel, Kasimir Wansing, Ahmed Ghallab, Marie Rosselin, Noemie Boissier, Irene Vignon-Clementel, Christian Hedberg, Fabian Geisler, Heribert Hofer, Peter Jansen, Stefan Hoehme, Dirk Drasdo, Jan Hengstler
Date Published: No date defined
Journal: Not specified
Citation: Intravital multi-modal flux analysis reveals the transport mechanism of bile acids through hepatic microconduits 63 : 951
Date Published: 17th Feb 2017
Authors: R. Apweiler, T. Beissbarth, M. R. Berthold, N. Bluthgen, Y. Burmeister, O. Dammann, A. Deutsch, F. Feuerhake, A. Franke, J. Hasenauer, S. Hoffmann, T. Hofer, Peter Jansen, Lars Kaderali, U. Klingmuller, Ulrike Koch, O. Kohlbacher, Lars Kuepfer, Frank Lammert, D. Maier, N. Pfeifer, N. Radde, M. Rehm, I. Roeder, J. Saez-Rodriguez, U. Sax, B. Schmeck, A. Schuppert, B. Seilheimer, F. J. Theis, J. Vera, O. Wolkenhauer
Date Published: 3rd Mar 2018
Journal: Exp Mol Med
PubMed ID: 29497170
Citation: Exp Mol Med. 2018 Mar 2;50(3):e453. doi: 10.1038/emm.2017.290.
Authors: Christian Hudert, S. Selinski, B. Rudolph, H. Blaker, C. Loddenkemper, R. Thielhorn, N. Berndt, K. Golka, C. Cadenas, J. Reinders, S. Henning, P. Bufler, Peter Jansen, Hergo Holzhütter, David Meierhofer, Jan Hengstler, S. Wiegand
Date Published: 18th Jan 2018
Journal: Liver Int
PubMed ID: 30444569
Citation: Liver Int. 2018 Nov 16. doi: 10.1111/liv.14006.